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RESEARCH ARTICLE
Protecting effect of PrP codons  
M142 and K222 in goats orally challenged 
with bovine spongiform encephalopathy prions
C. Fast1†, W. Goldmann2†, P. Berthon3†, K. Tauscher1†, O. Andréoletti4, I. Lantier3, C. Rossignol3, A. Bossers5, 
J. G. Jacobs5, N. Hunter2, M. H. Groschup1, F. Lantier3 and J. P. M. Langeveld5*
Abstract 
Breeding towards genetic resistance to prion disease is effective in eliminating scrapie. In sheep, classical forms of 
scrapie have been eradicated almost completely in several countries by breeding programs using a prion protein (PrP) 
gene (PRNP) amino acid polymorphism. For goats, field and experimental studies have provided evidence for several 
amino acid polymorphisms that are associated with resistance to scrapie, but only limited data are available concern-
ing the susceptibility of caprine PRNP genotypes to BSE. In this study, goat kids representing five PRNP genotypes 
based on three polymorphisms (M142, Q211 and K222 and the wild type I142, R211 and Q222) were orally challenged 
with bovine or goat BSE. Wild type goats were killed with clinical signs between 24–28 months post inoculation (mpi) 
to both challenges, and goats with genotype R/Q211 succumbed between 29–36 mpi. I/M142 goats developed 
clinical signs at 44–45 mpi and M/M142 goats remained healthy until euthanasia at 48 mpi. None of the Q/K222 goats 
showed definite clinical signs. Taken together the highest attack ratios were seen in wild type and R/Q211 goats, and 
the lowest in I/M142, M/M142 and Q/K222. In all genotype groups, one or more goats remained healthy within the 
incubation period in both challenges and without detectable PrP deposition in the tissues. Our data show that both 
the K222 and M142 polymorphisms lengthen the incubation period significantly compared to wild type animals, 
but only K222 was associated with a significant increase in resistance to BSE infection after oral exposure to both BSE 
sources.
© The Author(s) 2017. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Introduction
Prion diseases or transmissible spongiform encepha-
lopathies (TSEs) are caused by a unique infectious agent 
(“prion”) characterised by an entirely proteinaceous 
nature with apparent absence of functional nucleic 
acids [1, 2]. Disease transmission is possible within and 
between mammalian host species. Pivotal for transmis-
sibility is the host’s prion protein (PrP) that in its normal 
state is a cell membrane protein  (PrPC) to which recently 
several potential functions have been ascribed either in 
receptor mediation or immunological quiescence [3, 4]. 
In prion diseases  PrPC is converted into a stable “patho-
logical” conformer  (PrPSc), which is the diagnostic dis-
ease marker detectable in immunohistochemistry by its 
disease associated deposition patterns  (PrPD) and bio-
chemically by its aggregation properties and protease 
resistance of its C-terminal core region  (PrPres) [5–7].
The emergence of bovine spongiform encephalopa-
thy (BSE) in cattle and its subsequent transmission to 
humans as variant Creutzfeld–Jakob disease (vCJD) has 
proven that prion diseases represent a threat for man 
and other mammalian species [8, 9]. Goats represent the 
only other domestic ruminant species to be affected by 
BSE under field conditions [10–12]. Furthermore, goats 
are susceptible to classical scrapie although the disease 
occurs in Europe generally at 2–3 times lower preva-
lence than in sheep [13]. Susceptibility to TSE infection 
in sheep and goats has a strong genetic component that 
Open Access
*Correspondence:  jan.langeveld@wur.nl 
†C. Fast, W. Goldmann, P. Berthon and K. Tauscher contributed equally to 
the study
5 Wageningen BioVeterinary Research, Wageningen University & Research, 
Houtribweg 39, 8221RA Lelystad, The Netherlands
Full list of author information is available at the end of the article
Page 2 of 14Fast et al. Vet Res  (2017) 48:52 
potentially allows selection by breeding for resistance. 
The basis for this selection is the polymorphic character 
of the PrP amino acid sequence, because some of these 
PrP variants do not convert easily to  PrPSc [14]. Breed-
ing towards resistance has been successfully accom-
plished for sheep in some EU countries using the Q171R 
amino acid polymorphism as selection target, helped by 
the fact that the R171 allele appears to be dominant with 
almost complete protection to natural scrapie in R/R171 
homozygotes as well as in Q/R171 heterozygotes [13, 15, 
16].
A review of genotype surveys conducted worldwide 
revealed that on average almost 40% of goat PRNP 
sequences showed some variation of the amino acid 
sequence compared to the wild type [17, 18]. Case con-
trol studies have narrowed the potential candidates for 
resistance-associated polymorphisms to six amino acid 
changes: M142, S146, D146, H154, Q211 and K222 (wild 
type I142, N146, R154, R211 and Q222) [19–25]. It should 
be noted that wild type and variant PRNP alleles vary in 
codon 240 either encoding S240 or P240. While the wild 
type allele appears to split on average equally between 
S240 and P240 sequences, some of the variant alleles 
have so far only been observed in one combination, for 
example K222-S240. Association of codon 240 with TSE 
resistance is most likely weak or absent [19–21, 26]. The 
occurrence and frequencies of these PRNP alleles are 
breed and region dependent [27–29]. The strong genetic 
resistance to classical scrapie conferred by the K222 allele 
was corroborated by studies in goats using intracerebral 
and oral scrapie challenges with isolates from Italy, the 
USA or France [30–32].
We have previously published an interim report on a 
study of an oral challenge in goats with caprine BSE [33]. 
Here we report the final and full results of this study in 
which caprine and bovine BSE isolates were inoculated 
orally into goats of five different genotypes which were 
homozygous wild type (wt/wt) and M/M142 or heterozy-
gous I/M142, R/Q211 and Q/K222. The data provide 
convincing evidence that the K222 allele is the strongest 
protective factor in goats against BSE.
Materials and methods
Animals
Three different laboratories were involved in the chal-
lenges to exploit the available space: INRA Nouzilly, 
France (lab1), The Roslin Institute, UK (lab2) and FLI, 
Germany (lab3). Animal experimentation was performed 
according to European directive 2010/63/EU as well as 
in compliance with the respective national legislations in 
these countries (reference number for Germany LALLF 
7221.3-2.5-001/05, Animal & Scientific Procedures Act 
1986, UK). At INRA (France), all experiments were con-
ducted in accordance with the guidelines of the European 
Council Directive (86/609) and approved by the local eth-
ical committee; the animals were kept in Biosafety Level 
3 confined housing (PFIE, UE-1277, INRA Centre Val 
de Loire, Nouzilly, France). Goat kids of different breeds 
were obtained after weaning from the following sources: 
for lab1 and lab3 through Francis Barillet (goat produc-
tion at INRA Centre Val-de-Loire in Bourges Experimen-
tal Unit, INRA division of Animal Genetics) and for lab2 
through acquisition from UK holdings and through arti-
ficial insemination of females from the Roslin Institute. 
The animals belonged to the following breeds: Alpine, 
Saanen, Boer, Toggenburg and their crosses. Animals had 
been bred and selected based on their PRNP genotype, 
they were either I/M142, M/M142, R/Q211, Q/K222 or 
homozygous wild type for any of these codons (wt/wt). In 
total 129 animals were used in this study (Table 1).
Challenge and disease monitoring
Bovine and goat BSE brain materials were derived from 
clinically and  PrPSc—positive confirmed cases. The cat-
tle BSE homogenate for first passage was derived from 
a pool of two clinically affected UK BSE cases supplied 
by the VLA (now APHA, Weybridge, UK) (Table 1). The 
goat BSE homogenate for second passage was pooled 
brain material derived from three clinically and  PrPSc 
positive animals of wt/wt genotype following intracer-
ebral challenge with cattle BSE [34]. Animals were orally 
challenged twice with 1 g of bovine BSE in 10 mL physi-
ological saline solution with a 2  weeks interval (lab1, 
lab2) or only once with 1  g of goat BSE in 5  mL saline 
due to the lower amount of goat brain material available 
(lab2, lab3). During the incubation period, blood samples 
(lab1–3) as well as tonsil (lab1–3) and rectal (lab3) biop-
sies were taken on a regular scheme (Additional file  1). 
One to three animals per genotype were euthanized at 
first at pre-defined time points during the observation 
period. In addition goats were killed after showing con-
sistently clinical signs typical for BSE (i.e. neurological 
disorders such as abnormalities in sensation and move-
ment) or due to animal welfare reasons other than BSE. 
The last goats were killed due to animal welfare rea-
sons other than BSE at 81 mpi. Seven unchallenged wt/
wt goats (lab1 two, lab2 three, and lab3 two) and one 
unchallenged R/Q211 (lab3) shared the pens with chal-
lenged animals between 13 and 47 months of the inocu-
lation period to control for horizontal transmission. At 
necropsy a wide range of tissue samples were harvested 
under TSE-sterile conditions.
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Antibody sources
PrP specific antibodies used and their sources were: 
Bar224, Sha31 and SAF84 [35], 6C2 and 12B2 [36, 37], 
R145 [38], F99/97.6.1 [39], P4 and L42 [40], and 6H4 
[41]. R145 and F99/97.6.1 were epitope mapped by 
Pepscan analysis to the respective ovPrP sequences 
223RESQ226 and 221YQRE224 following published 
methods [42].
Histology and immunohistochemistry
The formalin fixed tissue samples were hematoxylin and 
eosin (H&E) stained and immunohistochemically (IHC) 
processed with well established procedures using PrP 
specific antibodies [38, 43, 44]. Methodological details 
are summarized in Additional file 1.
Biochemical analysis for scrapie‑BSE discrimination 
and in‑depth TSE typing
Brain stem samples of all animals were further exam-
ined by Western blot for discrimination between clas-
sical scrapie and BSE (Additional file  1) as described 
before [44–47]. Furthermore for in-depth TSE typing, 
triplex Western blot (triplex-WB) analyses were carried 
out as described before, using a mix of three antibodies, 
12B2, Sha31 and either SAF84 or F99 after first immuno-
complexing these respectively with Zenon labels Alexa 
647, 555, and 488 [48]. These antibodies are markers: 
(1) for presence of the N-terminal epitope (12B2) typi-
cal for classical scrapie but absent in classical BSE, and 
CH1641 scrapie, (2) the core region of  PrPres (Sha31), and 
(3) the presence of a second  PrPres population covering 
the C-terminal PrP region between the Sha31 epitope 
(sequence 148YEDRYYRE155, ovine numbering) and 
the C-terminus of mature PrP which is only recognized 
by antibodies like SAF84 and F99 (respective epitope 
sequences 166YRPVDQY171 and 221YQRE224) and 
which fragment is characteristic for CH1641 scrapie and 
H-type BSE. For comparison, reference samples used 
were: C-type, H-type and L-type BSE from cattle, and 
small ruminant BSE, classical scrapie, and CH1641 scra-
pie (sheep and/or goat) were used as in previous publica-
tions [31, 49].
Table 1 Experimental setup in the different labs performing the goat oral challenge
lab1 lab2 lab3
Experimental 
setup 1
st passage 2nd passage
Inoculum Cale BSE (UK) Goat BSE (gBSE-P12; wt/wt)
Inoculaon 2 × 1 g/goat, interval of 15 days 1 × 1 g/goat
Mode of 
inoculaon 10 mL/goat, (1:10 in glucose)
5 mL/goat, (1:5 
in saline)
Age at 
inoculaon 3–4 months 6–9 months 6–9 months 6–7 months
Goat breed Alpine, Saanen Saanen, Boer, Toggenburg Alpine–Saanen 
Number of goats and genotype
Total 38 27 24 40
wt/wt 12 12 11 15
I/M142 10 11
M/M142 4
R/Q211 12 11
Q/K222 12 11
Controls 2 (wt/wt) 1 (wt/wt) 2 (wt/wt) 3 (2 wt/wt, 1 R/Q211)
BSE, bovine spongiform encephalopathy; UK, United Kingdom; gBSE-P12, identification number of goat brain pooled homogenate; wt/wt, homozygous wild type; 
I/M142, heterozygous isoleucine/methionine genotype at codon 142; M/M142, homozygous methionine genotype at codon 142; R/Q211, heterozygous arginine/
glutamine genotype at codon 211; Q/K222, heterozygous glutamine/lysine genotype at codon 222.
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Mouse bioassay
In lab1 and lab3 mouse bioassays were performed at 6 and 
12 mpi with different tissues taken from respectively cat-
tle BSE and goat BSE infected goats to test for the even-
tual presence of infectivity in the early stage of disease 
incubation. In doing so transgenic mice overexpressing 
ovine (in lab1 Tg338 and in lab3 TgshpIX) and bovine PrP 
(in lab 1 Tg110) were used. All mouse lines are known to 
be highly sensitive for the detection of prion infectivity of 
different origin including BSE (Tg110 in [33], the Tg338 
and Tgshp IX in preparation by Nonno et al.). Addition-
ally end-point titration experiments with a goat BSE iso-
late were done using Tg110 [33] and TgshpIX mice (lab 
3, unpublished results), but data are not included here. 
The mice were intracerebrally inoculated (6–15 mice per 
sample, depending of the different lab schedules routinely 
done in France and Germany) with 20–30 µL of a 10% tis-
sue homogenate diluted in physiological saline [45, 50, 
51]. Subsequently all mice were clinically checked at least 
twice a week and either sacrificed due to animal welfare 
reasons or after 730 dpi at the latest. The mouse brains 
were subsequently tested for the presence of proteinase K 
resistant  PrPSc  (PrPres) by Western blot [44].
Statistical analysis
Differences in incubation period lengths were analysed 
for statistical significance with Student’s T test and signif-
icance for differences in distribution between healthy and 
disease animals by challenge and genotype groups were 
analysed with Fisher’s Exact Test for a 2 × 2 Contingency 
Table with two-tailed probability (p).
Results
Goat challenge results were classified in four health 
stage categories: (a) clinical—when consistent neuro-
logical signs pointing to a BSE infection were observed, 
(b) late preclinical—when no obvious clinical signs were 
observed but the animal appeared post mortem posi-
tive by IHC in the central nervous system (CNS), (c) 
early preclinical—when animals showed positivity by 
IHC in peripheral tissues but not yet in the CNS, and 
(d) healthy—without any of these markers. The occur-
rence of these categories in the time line after challenge 
of individual goats with their genotypes can be viewed 
in Additional file  2. Additionally, the time points men-
tioned below refer to the date of necropsy and subse-
quent prove of BSE infection by the detection of  PrPD in 
the brain stem. However, it has to be born in mind that 
some of these goats displayed the first clinical signs up to 
6–12 weeks before necropsy.
Goat challenges: first passage (bovine BSE)
Sixty-two animals were challenged with bovine BSE 
in lab1 and lab2. The goats were in five PRNP geno-
type groups: wt/wt (n = 24), I/M142 (n = 10), M/M142 
(n =  4), R/Q211 (n =  12) and Q/K222 (n =  12). Three 
unchallenged wild type animals were kept as contact con-
trols (Table 1). In total 22 animals were affected by BSE, 
while 40 goats and the controls remained completely 
negative with observation periods up to 48 months post-
inoculation (mpi) (Figure 1).
Clinical signs appeared in ten goats: five wt/wt goats 
at 25/26 mpi, three R/Q211 animals between 28–33 mpi 
Figure 1 Overview of the results of challenge with bovine BSE (1st passage) in goats with five different genotypes. Each symbol 
represents an individual goat. Symbol colours: empty, yellow, red and black represents TSE negative, preclinical  PrPD (positivity in peripheral sites), 
late preclinical  (PrPD positivity in CNS, no clear clinical signs) and clinical cases (these are also  PrPD positive in periphery and CNS). Symbol shapes 
represent location of experiment: circles, lab 1, triangles lab 2 (see also “Materials and methods” section). The two arrows under the X-axis: open and 
bold indicate respectively the month after inoculation at which respectively the first preclinical and clinical cases were observed.
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and even later at 44/45 mpi in two I/M142 goats. All 
clinically affected animals were  PrPD positive by immu-
nohistochemistry (IHC) in the central nervous system 
(CNS) and peripheral tissues in various combinations 
(see below).
A further nine animals were in a late preclinical state 
at necropsy and revealed  PrPD in brain stem as shown by 
IHC and/or biochemical analysis, but none of these goats 
showed clearly identifiable clinical signs typical for BSE. 
This group included two wt/wt goats sacrificed at 19 and 
36 mpi, five R/Q211 goats sacrificed at 17 (n = 2) and 25 
(n = 3) mpi, one Q/K222 goat killed at 43 mpi and one 
M/M142 goat killed at 48 mpi.
Another three wt/wt goats were in an early preclini-
cal state at 17 (n =  2) and 19 (n =  1), revealing weak 
amounts of  PrPD in different peripheral tissues only 
(see below). Samples from CNS and spleen from nine 
(3 wt/wt, 3 R/Q211, 3 Q/K222) healthy, BSE nega-
tive goats, which were culled at 6 mpi as part of the 
pathogenesis study, were examined by mouse bioassay 
using transgenic mouse lines Tg110 and Tg338. None 
of these mice showed clinical or pathological signs of a 
TSE infection.
The 40 non-affected animals were euthanized at vari-
ous time points with the longest survival times in the 
different genotypes as follows: 48 mpi for 2 wt/wt, one 
I/M142 and one M/M142, and 43 mpi for one Q/K222 
goat.
Because some animals were removed from the chal-
lenge groups at pre-defined post-inoculation times, 
attack ratios for preclinical, late preclinical and clini-
cal animals 12 mpi and later were only considered for 
estimation. These ratios were not less than 56% in wt/
wt, 25% in I/M142 goats, 25% in M/M142, 89% in R/
Q211, and 11% in Q/K222 goats (Table 2). These values 
decreased for four genotypes when only clinical positive 
animals were included: 28% in wt/wt, 0% in M/M142, 
33% in R/Q211 and 0% in Q/K222 goats.
Table 2 Data concerning the effectiveness of the oral challenges in goats with bovine (1st passage) and caprine (2nd pas-
sage) BSE
NA, not applicable.
a Statistical data: compared to the wild type group. Fisher’s exact test, *, **, and *** respectively p < 0.05, p < 0.01, p < 0.001.
b This Q/K222 goat was CNS- and muscle-positive.
c One Q/K222 case was CNS-positive, and psoas-muscle-positive but by mouse bioassay (Tg110) only [33]. If considered negative (by IHC) this group was statistically 
positive compared to the wild type group (p < 0.05).
Genotype Numbers Numbers from 12 mpi Inc. time clinical, mpi 
±SD (n)
Total Before 12 mpi After 12 mpi Pre‑clinical Late preclinical Clinical Attack ratios affected/
total (%) +  significancea
bovBSE
 wt 24 6 18 3 2 5 10/18 (56%) 25.2 ± 0.4 (5)
 I/M142 10 2 8 0 0 2 2/8 (25%)** 44.5 ± 0.7 (2)
 M/M142 4 0 4 0 1 0 1/4 (25%) NA
 R/Q211 12 3 9 0 5 3 8/9 (89%) 30.7 ± 2.1 (3)
 Q/K222 12 3 9 0 1b 0 1/9 (11%)** NA
gtBSE
 wt 26 6 20 2 3 5 10/20 (50%) 25.6 ± 1.5 (5)
 I/M142 11 3 8 0 0 0 0/8 (0%)* NA
 R/Q211 11 4 7 1 0 3 4/7 (57%) 34.3 ± 1.5 (3)
 Q/K222 11 3 8 0 1c 0 1/8 (13%)c* NA
Genotype Total mpi Numbers from 12 mpi Inc. time clinical, mpi 
±SD (n)
1st clin case Last clin 
case
Pre‑clinical Late preclini‑
cal
Clinical Attack ratios affected/
total (%) + significance
Combined challenges
 wt 50 24 28 5 5 10 20/38 (53%) 25.4 ± 1.1 (10)
 I/M142 21 44 45 0 0 2 2/16 (13%)** 44.5 ± 0.7 (2)
 M/M142 4 NA NA NA NA NA NA NA
 R/Q211 23 28 36 1 5 6 12/16 (75%) 32.5 ± 2.6 (6)
 Q/K222 23 43 NA 0 2 0 2/17 (12%)*** NA
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Goat challenges: second passage (goat BSE)
Fifty-nine goats were challenged with goat BSE in lab 2 
and lab 3. They were in four PRNP genotype groups: wt/
wt (n = 26), I/M142 (n = 11), R/Q211 (n = 11), and Q/
K222 (n = 11) (Table 1). Four wildtype and one R/Q211 
animals were kept as unchallenged contact controls. In 
total 15 animals were affected by a BSE infection, and 
44 goats and the controls remained completely negative 
within the observation period up to 81 mpi (Figure 2).
Clinical signs appeared in eight goats: five wt/wt goats 
between 24 and 28 mpi, and three R/Q211 animals 
between 33–36 mpi. All clinically affected animals were 
 PrPD positive by IHC in the CNS and in peripheral tis-
sues in various combinations (for details see below).
Additional four animals were in a late preclinical state 
at necropsy revealing  PrPD or infectivity in brain stem as 
shown by IHC. None of these goats showed clinical signs 
typical for BSE. This group included three wt/wt goats at 
19, 24 and 36 mpi as well as one Q/K222 goat at 45 mpi 
(infectivity data from this goat are published in [33]).
Two wt/wt goats (12 and 25 mpi) and one R/Q211 goat 
(12 mpi) were in an early preclinical state, revealing weak 
amounts of  PrPD in peripheral tissues only (for details see 
below). None of the I/M142 and Q/K222 goats showed 
clinical TSE signs.
Various samples from CNS (brain stem) and peripheral 
tissues (including samples from gut, lymphoreticular tis-
sues as well as autonomous nervous system) from two 
healthy and BSE negative wt/wt goats, which were culled 
at 12 mpi as part of the pathogenesis study, were exam-
ined by mouse bioassay using transgenic mouse lines 
TgshpIX. None of these mice showed clinical or patho-
logical signs of a TSE infection.
The 44 non-affected animals were euthanized at vari-
ous time points with the longest survival times in the 
different genotypes as follows: 81 mpi for one wt/wt and 
one Q/K222 goat, 47 mpi for three I/M142 goats and 77 
mpi for a R/Q211 goat.
Similar to the first passage BSE study, challenged ani-
mals 12 mpi and later were only considered for estima-
tion of attack ratios. These attack ratios for preclinical, 
late preclinical and clinical animals together were not 
less than 50% in wt/wt, 0% in I/M142 goats, 57% in R/
Q211, and 13% in Q/K222 goats (Table 2). Including only 
clinically positive animals reduced these values to 25% in 
wt/wt, 43% in R/Q211 and 0% in Q/K222 goats, while I/
M142 goats remained unchanged.
Statistical analysis
There was no statistically significant difference in the 
wild type challenge outcomes regarding the number 
of affected animals or the incubation period length of 
clinically affected goats between the two BSE isolates 
or between the three different laboratories. The small 
number of goats developing clinical disease made it dif-
ficult to analyse differences of incubation period length 
between genotypes.
Considering the period from 12 mpi, where the first 
preclinical signs appeared in the challenges (12mpi, in 
a wt and a R/Q211 goat), till the end of the experiments 
(see Figure 2) there were significant differences in attack 
ratios between wild type and QK222 groups in both chal-
lenges if only based on IHC observations (Table 2). The 
attack ratios values between wt and IM142 goats in goat 
BSE challenge were also statistically different (p < 0.05), 
but not after challenge with bovine BSE.
Figure 2 Overview of the results of challenge with goat BSE (= 2nd passage) in goats with four different genotypes. Each symbol 
represents an individual goat. Symbol colours and arrows are explained in Figure 1. Symbol shapes represent the laboratory of experiment: triangles 
lab 2, and squares lab 3. The two arrows under the X-axis: open and bold indicate respectively the month after inoculation at which respectively the 
first preclinical and clinical cases were observed. Small arrow near one Q/K222 symbol is reflecting the animal previously found weakly brain (only) 
positive in infectivity testing in Tg110 mice [33].
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Furthermore, differences became also apparent when 
the observation period was divided into early (12–30 
mpi) and late (> 30 mpi) phase and when both challenges 
were combined. In the early phase, infected animals 
were found only in wt/wt and R/Q211 goats at ratios of 
18/25 (72%) and 7/11 (64%), respectively; no infected ani-
mals occurred in genotypes I/M142 (0/4) and Q/K222 
(0/10). The difference between group I (wt/wt, R/Q211) 
and group II (I/M142, Q/K222) was highly significant 
(p < 0.0001).
The late phase showed no significant difference 
between group I and group II and all genotypes had 
infected animals. After 30 mpi, R/Q211 had a higher 
attack ratio of 5/7 (71%) than either wt/wt with 2/12 
(17%) or I/M142 with 2/12 (p = 0.03), but the difference 
to Q/K222 (2/7) was not significant. While the minimal 
attack ratio for R/Q211 was unchanged between the two 
observation phases, wt/wt genotypes were significantly 
less likely to be infected (p  <  0.002) once they had sur-
vived 30 mpi.
Immunohistochemistry
There were no distinct differences between the animals 
from the first and the second passage, therefore the 
immunohistochemical results will be presented for all 
groups together (see Additional files 3 and 4 for further 
details in respectively first and second passage results).
In total 30 goats revealed a clear  PrPD accumulation 
in the brain stem (CNS positive cases in Figure 3A). The 
degree of  PrPD deposition was associated with the clinical 
state of the animal. Thus, goats being in a late preclinical 
state showed a weak (n =  1), mild (n =  5) and moder-
ate (n = 4)  PrPD accumulation; only one R/Q211 goat and 
one Q/K222 goat (Figure  3B) were severely affected. In 
contrast, animals with clear clinical signs mostly exhib-
ited a severe  PrPD deposition (n = 16) and more rarely a 
moderate accumulation (n = 2). In most cases  PrPD accu-
mulation was widespread and involved the whole brain 
stem, both grey and white matter. In animals with only 
mild  PrPD accumulation, the most prominent deposi-
tions were seen in the dorsal motor nucleus of the vagus 
Figure 3 PrPD accumulation in central and peripheral nervous tissues of BSE infected goats. A Brain stem of a clinical goat BSE infected 
wt/wt goat, 24 mpi, showing a severe intra- and extracellular  PrPD accumulation. Antibody 6C2, bar 50 µm. B Brain stem of the late preclinical cattle 
BSE infected Q/K222 goat, 43 mpi, showing a severe intra- and extracellular  PrPD accumulation in the obex (DMNV). Antibody Bar224, bar 20 µm. C 
Spinal nerve of a clinical cattle BSE infected wt/wt goat, 25 mpi, showing moderate intra-axonal and intraglial  PrPD accumulation. Antibody Bar224, 
bar 100 µm. D Ileum of a clinical cattle BSE infected wt/wt goat, 25 mpi, showing  PrPD accumulation in neurons and glial cells of the enteric nervous 
system as well as intracellular in lymphoid cells of the ileal follicle. Antibody Bar224, bar 20 µm.
Page 8 of 14Fast et al. Vet Res  (2017) 48:52 
nerve (DMNV), the nucleus of the solitary tract, cuneate 
nucleus, hypoglossal nucleus, spinal tract nucleus and 
the olivary nuclei. Using antibodies specific for the PrP 
C-terminus which detect BSE associated  PrPD very well 
[52], intraneuronal, intraglial and cell-membrane-associ-
ated/extracellular fine to coarse  PrPD accumulations were 
seen in all brain areas examined.
Several peripheral lymphoreticular tissue sam-
ples were analysed for  PrPD accumulation, amongst 
them were mesenterial lymph nodes (MesLn), tonsil, 
ileum including Peyer’s patches (PP), rectal follicles 
(RAMALT), celiac and mesenteric ganglion complex 
(CMGC), ileal and rectal enteric nervous system (ENS), 
vagal nerve and brachial plexus, along with different 
skeletal muscles (Mm. oculomotorius, psoas major and 
semitendinosus) (Figure  4). The analysis of five wt/wt 
and one R/Q211 goat, which were negative in the brain 
stem, revealed  PrPD accumulations in the tonsil (n = 1), 
CMGC (n = 2) and ENS of the Ileum (n = 2) and in the 
ileal PP (n = 1).
The ileal ENS was the most frequently positive site 
(n  =  8) in the twelve late preclinical goats, which had 
only mild to moderate amounts of  PrPD in the brain stem. 
Only four animals showed a more widespread distribu-
tion of  PrPD involving the rectal ENS (n  =  1), MesLn 
(n = 2), ileal PP (n = 2) and tonsil (n = 2).
The positive Q/K222 goat (43 mpi) which was in a late 
preclinical state, showed a severe  PrPD accumulation 
in the brain, but no involvement of the LRS (Figure  5). 
The only peripheral tissues slightly positive are rectal 
ENS and different muscles (M. oculomotorius, M. psoas 
major).
Clinically ill wt/wt and R/Q211 goats (n  =  16) with 
moderate up to severe  PrPD accumulation in the brain 
Figure 4 PrPD accumulation in lymphoreticular tissues of BSE infected goats. A Spleen of a clinical cattle BSE infected wt/wt goat, 26 mpi. 
Antibody Bar224, bar 50 µm. B Mesenterial lymph node of a clinical cattle BSE infected R/Q211 goat, 30 mpi. Antibody bar 224, bar 20 µm. C Tonsil 
of a clinical cattle BSE infected I/M142 goat. Antibody R145, bar 50 µm. In all samples a mild to moderate  PrPD accumulation in follicles and in the 
sinus of the spleen can be seen.
Figure 5 PrPD accumulation in different skeletal muscles. A Ocular muscle of a Q/R211 goat infected with cattle BSE showing  PrPD accumula-
tion in muscle spindles, 28 mpi. Antibody Bar224, bar 20 µm. B Psoas muscle of a Q/K222 goat infected with cattle BSE showing weak  PrPD accumu-
lation in muscle spindles, 43 mpi. Antibody Bar224, bar 20 µm.
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stem, revealed a more widespread distribution of  PrPD in 
the LRS, ENS and different skeletal muscles with only five 
animals, in which  PrPD accumulations were confined to 
the ENS and PP of the gut. Two animals even showed a 
positive reaction in peripheral nerves. More interestingly 
are the two I/M142 goats, both with severely affected 
brains.  PrPD could be found in ileal ENS but not in the 
PP. Yet, one of these goats showed a mild  PrPD deposition 
in tonsil follicles.
In tissues of the LRS the  PrPD depositions were mostly 
confined to the follicles and rarely seen in the sinus. 
Reaction pattern seen is an intracellular fine to coarse 
granular staining in tingible body macrophages, follicular 
dendritic cells and few lymphocytes. Neuronal as well as 
glial cells were positive in the ENS (Figure 3), but in the 
CMGC only single neuronal cells showed a diffuse intra-
cellular pattern. Single muscle spindles revealed a mild 
accumulation of  PrPD (Figure 5).
Discriminatory analysis and TSE typing
Positivity in brain stem of all goats was analysed in the 
three laboratories, each with their own methodology to 
discriminate C-type BSE from classical scrapie (data not 
shown). Furthermore, in samples from goats of all gen-
otypes and both passage numbers the type of TSE was 
studied in more detail using as reference samples bovine 
C-type, H-type and L-type BSE, ovine and caprine BSE, 
classical scrapie, and CH1641 scrapie (Figure  6A). The 
low presence of 12B2 epitope (12B2/Sha31 signal ratio 
<  0.3), the glycoprofile expressed as the ratio between 
mono- and diglycosylated  PrPres (< 0.4, using glycoform 
fractions of total  PrPres in the Sha31 epitope detec-
tion) and the presence of only a single  PrPres population 
pointed out that all positive samples did show the charac-
ter of a C-type BSE infection (Figure 6B) [48, 49].
Discussion
This oral challenge study in goats elucidates the signifi-
cant protection conferred by the Q/K222 prion protein 
genotype against bovine and goat BSE infection admin-
istered through the oral route. There was no clear clini-
cal case with this genotype in 17 challenged animals, 
although it has to be considered that both late-preclinical 
Q/K222 goat from the bovine and caprine BSE challenges 
might have developed clinical disease at some later stage. 
I/M142 heterozygous genotypes appeared to provide par-
tial resistance, with two clinically positive cases. Includ-
ing the M/M142 late-preclinical case, M142 is also clearly 
associated with lengthened incubation periods in BSE 
similar to scrapie challenges [31].
While the R/Q211 genotyped goats exhibited extended 
incubation periods of the clinical cases by about 
5–9 months compared to the wild type goats in the two 
BSE challenges, it appeared that there was also a differ-
ence in the susceptibility beyond 30 months post inocu-
lation. In that late phase of the experiments, 2 out of 7 
(29%) animals survived BSE challenge in the R/Q211 
group only whereas in the wild type group 10 out of 12 
(83%) animals showed no signs of BSE infection. Addi-
tional amino acid polymorphisms in PRNP can be 
excluded as reason for a survival difference between the 
two genotypes, therefore other genetic loci might be 
involved [53]. It is unlikely though to be solely due to 
breed or laboratory differences as discussed below.
This study has been conducted in three laboratories 
in parallel following similar protocols as much as pos-
sible, but with different breeds of different regional ori-
gins, and different age groups. Despite this set-up, which 
was logistically necessary to conduct a challenge study of 
129 goat kids, significant differences were not observed 
between the laboratory groups as evidenced by a short 
mean incubation period and a narrow standard deviation 
(25.4 ± 1.1, Table 2) for the ten clinical cases of the wild 
type groups. This finding is supported by the fact that the 
tissue distribution did not reveal any remarkable devia-
tions between the different laboratories.
The goat kids used here were aged 3–9 months at chal-
lenge, depending on the lab involved. Previous findings in 
sheep and goats suggest that to achieve the highest attack 
rates in oral challenge, administration before weaning 
was important, possibly due to the developmental stage of 
the Peyer’s patches in the intestine [34, 54–56]. Although 
the exact response to challenge for the early age range 
was not known for goat kids, challenge of the kids before 
weaning was planned but could not be implemented due 
to logistic problems in animal movements. Nevertheless, 
the mean attack rate of 53% for all wild type animals in 
this study was distinctly higher than the 21% reported 
before for BSE challenged lambs of the 3–6  month age 
range [54]. It might reflect a higher intrinsic susceptibil-
ity of goats for oral challenge than sheep, which may also 
explain that BSE has only been identified in this species 
in natural conditions [10–12]. Taken together the data do 
not imply large variation due to selection of various age 
groups and breeds, but we cannot completely rule out 
that the sensitivity in the challenges of the five genotypes 
was reduced through an age effect.
Considering the successful transmissions in the differ-
ent genotypes, our data showed that clinical disease was 
appearing first in the wt/wt goats at 24–28 mpi with no 
differentiation between cattle BSE (first passage) and 
caprine BSE (second passage). This is rather surprising, 
as it has been shown previously that interspecies trans-
mission of TSEs results in long incubation periods, which 
usually shorten on further passages [57]. In particular, 
this result seems to contradict previous observations 
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Figure 6 Western blot: triplex Western blot analysis of goat BSE brain stem samples with three antibodies on one membrane. Samples 
from orally challenged goats were analysed together with a set of different types of TSEs from goat, sheep and cattle to illustrate the classical BSE 
like character in the BSE-challenged goats. A Analysis with a mixture of three antibodies with different PrP specificities: N-terminus (12B2), core 
(Sha31) and C-terminus (SAF84, lanes 1–16; or F99, lanes 17–19). Lanes: 1, 3–5, 19 goat BSE material from respectively wt/wt  2nd pass, R/Q211 
 2nd pass, wt/wt  2nd pass, R/Q211  2nd pass, Q/K222  1st pass; lane 6, classical scrapie from i.c. challenged R/Q211 goat; lane 7, CH1641 scrapie from 
i.c. challenge in wt/wt sheep; lane 8 CH1641 scrapie from i.c. challenge in wt/wt goat; lane 9 natural scrapie from wt/wt sheep; lane 10 BSE from 
i.c. challenged wt sheep  1st pass; lanes 14–16 respectively bovine C-type BSE, H-type BSE and L type BSE; lane 18, non-challenged goat material. 
Applied tissue equivalents were 0.5 mg, or (in lanes 3, 4, 14–16 and 19) 1 mg. Lanes 2, 11, 13, and 17, mol mass markers are indicated with their kDa; 
in lane 12, 15 ng rec-ovine PrP (wt). For linear epitope specificities of the antibodies, see paragraph Biochemical analysis of the Methods section. 
B Dot plots showing the TSE-type markers of individual samples derived from the antibody signals of  PrPres in triplex-WB. Each symbol represents 
the average signal ratio obtained from a triplicate analysis per individual sample (bars for the standard deviations). All orally challenged goats yield 
a typical C-BSE pattern for the markers N-terminus, glycoprofile and dual population independent of genotype and passage  (1st or  2nd). The 12 
analysed goat samples from the BSE challenges were: from  1st pass two wt/wt, two I/M142, three R/Q211, and one Q/K222 cases (open circles); from 
 2nd pass three wt/wt, and one R/Q211 cases (closed black circles).
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in transgenic mice expressing bovine PrP (Tg110), 
in which sheep- or goat-passaged BSE would lead to 
shorter incubation times than bovine BSE [58, 59]. Dif-
ferences between the two challenge conditions or titre 
of the challenge materials might have played a role. On 
the other hand, this phenomenon may well be the result 
of intracerebral administration in the mice, whereas BSE 
transmissibility through the oral route might be more 
dependent of host factors encountered in the LRS and 
ENS before entering the CNS [60]. However, a similar 
pattern of adaption has been observed in vitro by serial 
PMCA [60]. Overall, these results imply that passage of 
BSE through wt/wt and R/Q211 goats will not necessarily 
lead to a measurable adaptation of the BSE agent to goat. 
Overall, the incubation period of the wild type goats is 
very similar to sheep with the same PRNP genotype [54, 
61–63].
The immunohistochemical data did not show differ-
ences between the genotypes or between the laboratories 
involved. More surprising are the results concerning the 
tissue distribution of  PrPD. This regards both the time 
course of the disease and the tissues involved. Even weak 
 PrPD accumulations in peripheral tissue samples were not 
seen before 12 mpi and only in a single animal. Further-
more, late preclinical goats, which already have a mild 
to moderate accumulation of  PrPD in the CNS, not only 
showed a minor involvement of peripheral tissue sam-
ples, but in most cases even a confinement of the  PrPD 
accumulations to the Peyer’s patches and enteric nerv-
ous system of the gut. Only a few animals revealed a mild 
 PrPD positive staining reaction in other lymphoid tissues, 
i.e. tonsil and mesenteric lymph nodes. A more wide-
spread distribution of  PrPD in lymphoid tissues was only 
seen in a few clinical goats, late in the incubation period. 
This is in clear contrast to classical scrapie in sheep and 
goats as well as BSE in sheep [25, 44, 62, 64]. This unusual 
 PrPD distribution pattern is reflected by examinations 
addressing the infectivity in peripheral tissue samples. 
As described by [33] and shown by results presented 
here none of the samples examined from goats early in 
the incubation period (6 and 12 mpi) revealed any signs 
of infectivity, neither in Tg110, Tg338 nor Tgshp IX. On 
the other hand similar to the results seen in immunohis-
tochemistry a more widespread distribution of BSE infec-
tivity was seen in different peripheral tissue samples of 
clinical goats among others the popliteal lymph node of 
goats with different genotype [33] and in the spleen of a 
wild type goat (lab 3, data not shown).
A French study showed that the time course of the 
scrapie pathogenesis is slightly prolonged in goats as 
compared to sheep [65]. However, the spread of the scra-
pie agent during the incubation time was quite similar 
[25, 44, 66]. This was also observed in BSE affected sheep 
[61, 63].  PrPD accumulations are widespread with dis-
tinct  PrPD depositions in follicles and neurons, involving 
several tissues of the lymphoreticular system as well as 
the autonomous nervous system early in the incubation 
period [25, 44, 61, 63, 66]. In other words TSE neuroin-
vasion in sheep and goats normally did not occur until 
a high proportion of lymphoid tissues was positive [66]. 
On the other hand BSE in cattle spreads almost solely 
along the autonomous nervous system, with Peyer’s 
patches of the gut as the only lymphoid tissues regu-
larly involved [36, 67]. Unfortunately, CMGC, as a rep-
resentative sample for the autonomous nervous system, 
was not available for all goats. However, weak  PrPD accu-
mulations were seen in two preclinical goats, distinct 
accumulation in one late preclinical goat as well as in all 
available samples of the clinical goats (data not shown). 
Thus, the pathogenesis seen in our BSE infected goats, 
with no major involvement of the lymphoreticular sys-
tem is more reminiscent of the disease in cattle. This is 
supported by the observation that one clinical I/M142 
and two late preclinical (one Q/K222 and one M/M142) 
goats showed no involvement of the LRS at all, even with 
severe  PrPD accumulation in the brain stem. It should 
be noted that the second clinical I/M142 goat revealed 
a slight staining reaction in rectal follicles and in tonsil. 
From this point, it remains a speculation what might be 
the reason behind this unusual distribution pattern in the 
LRS of BSE infections and, as described by others [66], 
some scrapie infected goats. There might be an inability 
of goat lymphoid tissues to accumulate certain  PrPD’s. On 
the other hand it is also conceivable that the low amounts 
of  PrPD detectable in the LRS are due to better clearance 
abilities in those goats. The animal numbers here are too 
low to reach a conclusion on the extent to which this pat-
tern is influenced by the genotype, but a similar pattern 
has been reported before [66].
The two I/M142 with clinical disease and the Q/K222 in 
the late preclinical state of infection showed incubation 
times at 44 mpi and 43 mpi, respectively. In the goat BSE 
challenges clinical signs were not recorded for any of the 
I/M142 and Q/K222 carriers, but a confirmation by IHC 
of  PrPD in the CNS of an M/M142 goat at 48 mpi and by 
mouse bioassay of low level infectivity in the CNS of a 
Q/K222 goat at 45 mpi [33] (see arrow in Figure 2) was 
possible. Therefore, as shown previously for goat scrapie 
[24, 30, 31], not only the attack ratios but also the incuba-
tion periods of BSE in goats appeared influenced by these 
genotypes. Low attack rates leading to few infected ani-
mals and even fewer clinical cases with long incubation 
periods provides valuable data in support of a protec-
tive effect against BSE infection by the M142 and K222 
variants. By necessity, our study was mostly conducted in 
heterozygous goats and both polymorphisms, M142 and 
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K222, showed a dominant phenotype as expected from 
goat scrapie studies and sheep TSE challenges [30, 31, 
68]. Resistance to scrapie in the presence of either allele 
has been shown in many case–control studies and, due to 
the relative low genotype frequency of homozygotes, the 
association with resistance has been significant mostly 
for heterozygotes [15, 20, 32, 54]. The survival of the four 
M/M142 to 48 mpi without clinical disease suggests that 
homozygotes are at least as resistant to BSE as heterozy-
gotes, which is also evident for scrapie [25]. Similar data 
for oral BSE exposure of K/K222 goats are still missing, 
but an attack ratio of 1/5 and an incubation period of 69 
mpi for intracerebral inoculation with scrapie [31] com-
bined with evidence that transgenic mice expressing only 
caprine K222 PrP were resistant to bovine BSE increases 
the likelihood that K/K222 goats will show significant 
resistance to BSE too [58]. Of course, this is crucial as 
breeding programs designed to increase the K222 allele 
frequency will inevitably lead to an increase in the num-
ber of homozygous K/K222 animals in goat populations. 
As a polymorphism that protects from scrapie and BSE, 
K222 is the strongest candidate for breeding programs 
for the eradication of TSEs from goats.
However, the K222 allele is not always available for 
TSE—resistance breeding, since it occurs in variable and 
often very low frequencies in the European goat popu-
lation. It varies even within seemingly similar breeds 
depending on their geographical locations [17, 18, 27, 
29]. Introduction of this variant into goat populations 
with an endemic scrapie problem may be worth consider-
ing. The use of alternative PrP polymorphisms associated 
with a protective effect at least for classical scrapie such 
as N146D and N146S may be possible for a restricted 
range of breeds [69, 70].
Our challenge data further strengthen the view that the 
caprine K222 allele is an attractive PRNP variant for TSE 
resistance breeding since it is not only strongly limiting 
the transmission of classical scrapie, but as is exemplified 
here it also has a protective effect against BSE infection.
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